|
US6602677B1
(en)
|
1997-09-19 |
2003-08-05 |
Promega Corporation |
Thermostable luciferases and methods of production
|
|
WO2004063344A2
(en)
|
2003-01-10 |
2004-07-29 |
Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health |
CATALYTIC DOMAINS OF β/1,4)-GALACTOSYLTRANSFERASE I HAVING ALTERED DONOR AND ACCEPTOR SPECIFICITIES, DOMAINS THAT PROMOTE IN VITRO PROTEIN FOLDING, AND METHODS FOR THEIR USE
|
|
US8759490B2
(en)
|
2005-03-24 |
2014-06-24 |
Millennium Pharamaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
US8323645B2
(en)
|
2005-03-24 |
2012-12-04 |
Millennium Pharmaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
WO2007067991A2
(en)
|
2005-12-08 |
2007-06-14 |
Medarex, Inc. |
Human monoclonal antibodies to o8e
|
|
US9121853B2
(en)
|
2006-03-20 |
2015-09-01 |
Mayo Foundation For Medical Education And Research |
B7-H4 expression on tumor vasculature
|
|
EP2124998B8
(en)
|
2006-12-27 |
2015-05-06 |
The Johns Hopkins University |
Methods for detecting inflammation and auto-immune diseases
|
|
CL2008003526A1
(es)
|
2007-11-30 |
2010-01-11 |
Medarex Inc |
Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer.
|
|
WO2009102820A2
(en)
|
2008-02-11 |
2009-08-20 |
Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services |
Modified sugar substrates and methods of use
|
|
US8852599B2
(en)
|
2011-05-26 |
2014-10-07 |
Bristol-Myers Squibb Company |
Immunoconjugates, compositions for making them, and methods of making and use
|
|
WO2012171020A1
(en)
|
2011-06-10 |
2012-12-13 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
US9676854B2
(en)
|
2011-08-15 |
2017-06-13 |
Medimmune, Llc |
Anti-B7-H4 antibodies and their uses
|
|
GB201115841D0
(en)
|
2011-09-13 |
2011-10-26 |
Genovis Ab |
Protein and method
|
|
US9422351B2
(en)
|
2011-11-03 |
2016-08-23 |
The Trustees Of The University Of Pennsylvania |
Isolated B7-H4 specific compositions and methods of use thereof
|
|
CA2894879A1
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
|
JP6436965B2
(ja)
|
2013-03-14 |
2018-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｂ７−ｈ４抗体及びイムノコンジュゲート
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
KR102087850B1
(ko)
|
2013-10-11 |
2020-03-12 |
메르사나 테라퓨틱스, 인코포레이티드 |
단백질-고분자-약물 접합체
|
|
WO2016040724A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
|
US10626176B2
(en)
|
2014-10-31 |
2020-04-21 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind B7-H4
|
|
WO2016170186A1
(en)
*
|
2015-04-23 |
2016-10-27 |
Synaffix B.V. |
PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE
|
|
ES2972511T3
(es)
|
2016-02-08 |
2024-06-13 |
Synaffix Bv |
Enzimas para el corte de glicoproteínas
|
|
CN109563503B
(zh)
|
2016-07-26 |
2023-09-29 |
静冈县 |
抗b7-h4抗体
|
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
|
EP3612567B1
(en)
|
2017-04-19 |
2024-09-11 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
|
US10814011B1
(en)
|
2017-06-16 |
2020-10-27 |
Nantbio, Inc. |
Anti-B7-H4 antibodies and methods
|
|
US11306144B2
(en)
|
2017-08-25 |
2022-04-19 |
Five Prime Therapeutics, Inc. |
B7-H4 antibodies and methods of use thereof
|
|
CN112566934B
(zh)
|
2018-01-23 |
2024-09-17 |
奈斯科尔公司 |
B7-h4抗体及其使用方法
|
|
CN116693686A
(zh)
|
2018-02-11 |
2023-09-05 |
江苏豪森药业集团有限公司 |
抗b7-h4抗体、其抗原结合片段及其医药用途
|
|
BR112020016986A2
(pt)
|
2018-02-21 |
2021-03-02 |
Five Prime Therapeutics, Inc. |
formulações de anticorpo contra b7-h4
|
|
CA3091161A1
(en)
|
2018-02-21 |
2019-08-29 |
Five Prime Therapeutics, Inc. |
B7-h4 antibody dosing regimens
|
|
CN108948204B
(zh)
|
2018-06-15 |
2023-01-13 |
苏州旭光科星抗体生物科技有限公司 |
抗人b7-h4单克隆抗体、鉴定方法、应用和试剂盒
|
|
KR20210076025A
(ko)
|
2018-10-15 |
2021-06-23 |
파이브 프라임 테라퓨틱스, 인크. |
암 병용 요법
|
|
CN113365664A
(zh)
|
2018-10-29 |
2021-09-07 |
梅尔莎纳医疗公司 |
具有含肽接头的半胱氨酸工程化的抗体-药物缀合物
|
|
US20230072897A1
(en)
|
2019-06-06 |
2023-03-09 |
Shanghai Hansoh Biomedical Co., Ltd. |
Anti-b7-h4 antibody-drug conjugate and medicinal use thereof
|
|
BR112022013255A2
(pt)
|
2020-01-09 |
2022-09-06 |
Mersana Therapeutics Inc |
Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo
|
|
US20230112085A1
(en)
|
2020-01-30 |
2023-04-13 |
Apeximmune Therapeutics Inc. |
Anti-b7-h4 constructs and uses thereof
|
|
MX2022009936A
(es)
|
2020-03-18 |
2022-09-12 |
Genmab As |
Anticuerpos que se unen al dominio v-set que contiene el inhibidor de activacion de celulas t 1 (b7h4).
|
|
IL296901A
(en)
|
2020-04-02 |
2022-12-01 |
Mersana Therapeutics Inc |
Antibody-drug conjugates comprising sting agonists
|
|
JP7726534B2
(ja)
|
2020-06-30 |
2025-08-20 |
諾納生物（蘇州）有限公司 |
抗ｂ７ｈ４抗体及びその二重特異性抗体および用途
|
|
MX2023008000A
(es)
|
2021-01-04 |
2023-07-13 |
Mersana Therapeutics Inc |
Conjugados de anticuerpo dirigido a b7-h4 y farmaco, y metodos de uso de los mismos.
|